These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 9422443)
41. [What can be expected of intracavernous injections?]. Jardin A; Bensadoun H; Benoit G; Puech A; Alexandre L Acta Urol Belg; 1988; 56(2):265-71. PubMed ID: 2969665 [No Abstract] [Full Text] [Related]
42. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184 [TBL] [Abstract][Full Text] [Related]
44. [Injections into the corpora cavernosa. The pros and cons]. Doremieux J; Reziciner S; Grinenwald P; Bondil P Ann Urol (Paris); 1987; 21(6):429-34. PubMed ID: 3435063 [TBL] [Abstract][Full Text] [Related]
46. [Injection of papaverine in the cavernous body of the penis in the treatment of impotentia erigendi]. van Driel MF; Zwiers W; Hooykaas JA; Brouwer OF; Boonstra S Ned Tijdschr Geneeskd; 1986 Sep; 130(37):1647-9. PubMed ID: 3762769 [No Abstract] [Full Text] [Related]
47. Vasoactive intracavernous pharmacotherapy--the nursing role in teaching self-injection therapy. Duffy LM; Sidi AA; Lange PH J Urol; 1987 Nov; 138(5):1198-200. PubMed ID: 3669166 [TBL] [Abstract][Full Text] [Related]
48. Intracavernosal injections and fibrosis: myth or reality? Tal R; Mulhall JP BJU Int; 2008 Aug; 102(5):525-6. PubMed ID: 18485038 [No Abstract] [Full Text] [Related]
49. Oral terbutaline in the management of pharmacologically induced prolonged erection. Priyadarshi S Int J Impot Res; 2004 Oct; 16(5):424-6. PubMed ID: 14999218 [TBL] [Abstract][Full Text] [Related]
50. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. McMahon CG; Samali R; Johnson H J Urol; 2000 Oct; 164(4):1192-6. PubMed ID: 10992364 [TBL] [Abstract][Full Text] [Related]
51. Current treatment and future perspectives for erectile dysfunction. Hatzichristou DG Int J Impot Res; 1998 May; 10 Suppl 1():S3-13. PubMed ID: 9669215 [TBL] [Abstract][Full Text] [Related]
52. [Comparing effect in the management of erectile dysfunction by using 2 sets of drugs of intracavernosal injection]. Jian HY; Hao JC Zhonghua Nan Ke Xue; 2003 Jun; 9(3):200-1. PubMed ID: 12861835 [TBL] [Abstract][Full Text] [Related]
53. What is the current role of intracavernosal injection in management of erectile dysfunction? El-Sakka AI Int J Impot Res; 2016 May; 28(3):88-95. PubMed ID: 27076113 [TBL] [Abstract][Full Text] [Related]
54. Self-injection devices for intracavernosal pharmacotherapy: operational classification and safety considerations. Pescatori ES; Calpista A; Artibani W; Pagano F; Calabro A Int J Impot Res; 1996 Jun; 8(2):53-7; discussion 57-8. PubMed ID: 8858390 [TBL] [Abstract][Full Text] [Related]
55. Chemical prosthesis. Zenico T; Zoli M; Maltoni G Acta Urol Belg; 1989; 57(1):223-6. PubMed ID: 2718845 [TBL] [Abstract][Full Text] [Related]
56. Patient-reported pain with initial intracavernosal injection. Albaugh J; Ferrans CE J Sex Med; 2009 Feb; 6(2):513-9. PubMed ID: 19215617 [TBL] [Abstract][Full Text] [Related]
58. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Porst H Int J Impot Res; 2000 Oct; 12 Suppl 4():S91-S100. PubMed ID: 11035394 [TBL] [Abstract][Full Text] [Related]
59. Intracavernosal therapy for erectile failure, impact of treatment and reasons for drop-out and dissatisfaction. Porst HC Int J Impot Res; 2000 Apr; 12(2):131. PubMed ID: 11052642 [No Abstract] [Full Text] [Related]
60. The Autoinjector device: an aid to intracavernosal pharmacotherapy. Gilbert HW; Gingell JC Br J Urol; 1992 Aug; 70(2):211-2. PubMed ID: 1393452 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]